Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

ScanSource Posts Strong Quarterly Finish Amid Annual Revenue Decline

Dieter Jaworski by Dieter Jaworski
September 4, 2025
in Earnings, Tech & Software, Trading & Momentum
0
ScanSource Stock
0
SHARES
201
VIEWS
Share on FacebookShare on Twitter

Technology distributor ScanSource concluded its fiscal year 2025 with a surprisingly robust final quarter. Although annual revenue experienced a contraction, profitability saw significant improvement, driven by a strategic company-wide shift toward recurring revenue streams.

Annual Performance: A Contrast in Results

A review of the full fiscal year presents a nuanced financial picture. Total annual revenue declined by 6.7 percent, settling at $3.04 billion. Despite this top-line decrease, the company achieved a notable improvement in its bottom line. Gross profit for the year advanced by 2.4 percent to $408.6 million.

This enhanced profitability, reflected in a gross margin increase from 12.2% to 13.4%, is attributed to the strategic pivot toward more predictable, recurring income. This high-margin revenue stream surged by an impressive 31.8 percent year-over-year, making the company’s financial performance less dependent on volatile project-based business.

Key annual financial metrics include:
* Annual Revenue: $3.04 billion (-6.7%)
* Adjusted EBITDA: $144.7 million (+2.8%)
* Non-GAAP EPS: $3.57 (+15.9%)
* Free Cash Flow: ~$104.1 million

Final Quarter Exceeds Projections

The company’s fourth-quarter performance notably surpassed market expectations. Net sales climbed 8.9 percent to reach $812.9 million, exceeding analyst forecasts. The specialty technology segment was a particular standout, registering 9.2 percent growth. This expansion was fueled by robust demand for mobility solutions, barcode technology, and physical security equipment.

Should investors sell immediately? Or is it worth buying ScanSource?

Profitability metrics were even more striking. Non-GAAP earnings per share (EPS) jumped to $1.02, a substantial increase from $0.80 reported in the same quarter last year. Even on a GAAP basis, EPS reached $0.88, representing a 37.5 percent gain.

Additional quarterly highlights were:
* Gross Profit: $105.1 million (+8.0%)
* Adjusted EBITDA: $38.6 million (+13.0%)

Confident Guidance for Fiscal 2026

Looking ahead, ScanSource’s leadership has issued an optimistic outlook for the new fiscal year. The company anticipates revenue to land between $3.1 billion and $3.3 billion. Adjusted EBITDA is projected to be in the range of $150 million to $160 million, with plans to generate a minimum of $80 million in free cash flow.

This forward guidance suggests the positive trend in profitability is expected to continue, even if overall revenue growth remains moderate. The company’s strategic focus on higher-margin, recurring business appears to be delivering tangible financial benefits.

Ad

ScanSource Stock: Buy or Sell?! New ScanSource Analysis from February 8 delivers the answer:

The latest ScanSource figures speak for themselves: Urgent action needed for ScanSource investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

ScanSource: Buy or sell? Read more here...

Tags: ScanSource
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Next Post
Compass Therapeutics Stock

A Closer Look at Compass Therapeutics' Clinical and Financial Trajectory

Coinbase Stock

Coinbase's Strategic Pivot: Blending Tech Titans with Digital Assets

Alibaba Stock

Alibaba Shares Surge as Artificial Intelligence Investments Deliver Results

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com